Literature DB >> 2667794

Advances in cyclosporine pharmacology, measurement, and therapeutic monitoring.

L M Shaw1.   

Abstract

This review will focus on our current state of understanding of the cellular and molecular mechanisms by which CsA exerts immunosuppression and will present new information on: pharmacokinetic variability of CsA, selection of specimen and method for measuring CsA concentration, identity of CsA metabolites and their immunosuppressive and toxic activity, and the relationship between steady-state pre-dose concentrations of CsA in blood and response to treatment in transplant patients.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2667794

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


  15 in total

Review 1.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA.

Authors:  A Zeevi; G Eiras; F H Bach; J J Fung; S Todo; T Starzl; R J Duquesnoy
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

Review 3.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  Kinetic analysis of molecular interconversion of immunosuppressant FK506 by high-performance liquid chromatography.

Authors:  T Nishikawa; H Hasumi; S Suzuki; H Kubo; H Ohtani
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

Review 5.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

Review 6.  Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration.

Authors:  Melanie Gerard; Angélique Deleersnijder; Jonas Demeulemeester; Zeger Debyser; Veerle Baekelandt
Journal:  Mol Neurobiol       Date:  2011-05-07       Impact factor: 5.590

Review 7.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

8.  Diltiazem co treatment with cyclosporine for induction of disease remission in sight-threatening non-infectious intraocular inflammation.

Authors:  Usama Shalaby
Journal:  Jpn J Ophthalmol       Date:  2016-12-10       Impact factor: 2.447

9.  Effects of cyclosporine A on chick osteoclasts in vitro.

Authors:  M H Chowdhury; V Shen; D W Dempster
Journal:  Calcif Tissue Int       Date:  1991-10       Impact factor: 4.333

10.  Chronopharmacokinetics of Cyclosporine A in the Wistar rat following oral administration.

Authors:  M F Malmary; K Kabbaj; C Labat; A Batalla; I Houti; S Moussamih; J Oustrin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.